Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 3/20 | 0.57 |
| ▸ | ITGB3 | P05106 | 12/20 | 0.42 |
| ▸ | ITGA2B | P08514 | 12/20 | 0.42 |
| ▸ | ITGA2 | P17301 | 3/20 | 0.42 |
| ▸ | STK33 | Q9BYT3 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4303895 | 0.88 | F10 (0.56) | F10STK33ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL4309505 | 0.86 | PARP1 (0.44) | F10ITGB3ITGA2BITGA2ALDH1A1 | |
| SCHEMBL13950028 | 0.83 | F10 (0.52) | F10KDM4E | |
| SCHEMBL4314194 | 0.83 | F10 (0.55) | F10ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL4313283 | 0.83 | F10 (0.53) | F10STK33ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL4305977 | 0.83 | ACHE (0.54) | F10STK33ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL13970574 | 0.83 | F10 (0.51) | F10ALDH1A1HPGDSMN1; SMN2KDM4E | |
| SCHEMBL5784301 | 0.80 | F10 (0.55) | F10STK33ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL13950127 | 0.79 | F10 (0.52) | F10STK33ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL6214821 | 0.79 | ITGB3 (0.40) | F10ITGB3ITGA2BITGA2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7482472-B2 | Substituted isoindoles and their use | BAYER HEALTHCARE AG (DE) | 2009-01-27 | — | — | US | disclosed |
| US-20080039446-A1 | Substituted isoindoles and their use | BAYER HEALTHCARE AG (DE) | 2008-02-14 | — | — | US | disclosed |
| US-7189738-B2 | Substituted isoindoles and their use thereof | BAYER HEALTHCARE AG (DE) | 2007-03-13 | — | — | US | disclosed |
| EP-1414817-B1 | substituted isoindoles and the use thereof | BAYER HEALTHCARE AG (DE) | 2005-04-06 | — | — | EP | disclosed |
| US-20040215019-A1 | Substituted isoindoles and the e use thereof | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-10-28 | — | — | US | disclosed |
| EP-1414817-A1 | SUBSTITUTED ISOINDOLES AND E USE THEREOF | Bayer HealthCare AG (DE) | 2004-05-06 | — | — | EP | disclosed |
| WO-2003011858-A1 | SUBSTITUTED ISOINDOLES AND E USE THEREOF | BAYER HEALTHCARE AG (DE) | 2003-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039446-A1 | Substituted isoindoles and their use | F2, F12, TFPI2 | F10 19/4885ITGB3 767/4885ITGA2B 513/4885 |
| US-20040215019-A1 | Substituted isoindoles and the e use thereof | F2, F12, F5 | F10 14/4885ITGB3 662/4885ITGA2B 424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.